COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S EVAX (“Evaxion” or the “Company”), a clinical-stage biotechnology company focused on the development of AI-driven immunotherapies, announces that its new Chief Executive Officer (CEO), Per Norlén, will join the… company has occurred.
dr Norlén is a board-certified physician and associate professor with more than 20 years of experience in the biotechnology sector, including the last decade in senior leadership positions. He brings a wealth of experience from serving as CEO of public drug development companies. He has a proven track record of business development including key biotech and pharma out-licensing deals.
“Evaxion has evolved from an under-the-radar start-up into a clinical-stage biotech company that is a leader in developing customized cancer immunotherapies that are individually tailored to each patient. I am convinced that Evaxion is on to something extremely important that has the potential to be a game changer for patients with metastatic cancer.Throughout my career to date, I have always dreamed of creating the perfect drug and I feel enormously privileged “To now be part of a team that I believe is doing just that with a newly initiated phase 2b study in melanoma that will hopefully confirm the very promising phase 1 proof of concept is clearly within reach,” says Per Norlen, CEO of Evaxion.
CEO Marianne Soegaard says the new hire signals the next step for the biotech company:
“With Per at the helm, we expect to take our promising clinical and preclinical results to the next level. Evaxion is a deeply innovative and talented company that works tirelessly to save patients’ lives. Per Norlén joins the company as an experienced executive with the necessary knowledge and skills to take Evaxion from an innovative early stage to the next level. I look forward to having Per on board to leverage the tremendous potential of our…
